Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001069530-22-000023
Filing Date
2022-05-05
Accepted
2022-05-05 09:12:37
Documents
66
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sava-20220331x10q.htm   iXBRL 10-Q 1835014
2 EX-31.1 sava-20220331xex31_1.htm EX-31.1 25544
3 EX-31.2 sava-20220331xex31_2.htm EX-31.2 25243
4 EX-32.1 sava-20220331xex32_1.htm EX-32.1 20426
5 GRAPHIC sava-20220331x10qg001.jpg GRAPHIC 28862
6 GRAPHIC sava-20220331x10qg002.jpg GRAPHIC 30381
7 GRAPHIC sava-20220331x10qg003.jpg GRAPHIC 46460
8 GRAPHIC sava-20220331x10qg004.jpg GRAPHIC 31851
9 GRAPHIC sava-20220331x10qg005.jpg GRAPHIC 93477
  Complete submission text file 0001069530-22-000023.txt   6839999

Data Files

Seq Description Document Type Size
10 EX-101.SCH sava-20220331.xsd EX-101.SCH 32706
11 EX-101.CAL sava-20220331_cal.xml EX-101.CAL 42861
12 EX-101.DEF sava-20220331_def.xml EX-101.DEF 117864
13 EX-101.LAB sava-20220331_lab.xml EX-101.LAB 253179
14 EX-101.PRE sava-20220331_pre.xml EX-101.PRE 246544
60 EXTRACTED XBRL INSTANCE DOCUMENT sava-20220331x10q_htm.xml XML 1195183
Mailing Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731
Business Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-29959 | Film No.: 22894464
SIC: 2834 Pharmaceutical Preparations